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Abstract
Background: Cirrhosis is associated with angiogenesis and disruption of hepatic vascular architecture. Yiguanjian
(YGJ) decoction, a prescription from traditional Chinese medicine, is widely used for treating liver diseases. We
studied whether YGJ or its ingredients (iYGJ) had an anti-angiogenic effect and explored possible mechanisms
underlying this process.
Methods: Cirrhosis was induced with carbon tetrachloride (CCl4) (ip) in C57BL/6 mice for 6 weeks. From week 4 to
week 6, cirrhotic mice were randomly divided into four groups: sorafenib-treated, YGJ-treated and iYGJ-treated mice
and placebo. Serum biochemistries, hydroxyproline (Hyp) content and histopathological changes of hepatic tissues
were measured as were α-smooth muscle actin (α-SMA), collagen I, CD31, vascular endothelial growth factor (VEGF),
VEGF receptor (VEGFR) 2 and hypoxia-inducible factor (HIF)-1α.
Results: Both YGJ and iYGJ improved serum biochemistries. Changes of histopathology showed that YGJ and
iYGJ reduced hepatic tissue necroinflammatory and collagen fiber deposition in cirrhosis mice. Compared to the
CCl4 treated animals, Hyp, α-SMA, collagen I, CD31, VEGF, VEGFR, and HIF-1α expression decreased in YGJ and
iYGJ groups.
Conclusions: YGJ and iYGJ inhibited liver angiogenesis in cirrhotic mice treated with CCl4 by inhibiting the
HIF-1α/VEGF signaling pathway, suggesting that anti-angiogenic effects of YGJ and iYGJ are associated with
improving the hepatic hypoxic microenvironment.
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Background
One theory underlying the pathogenesis of cirrhosis is
angiogenesis and disruption of hepatic vascular archi-
tecture. The increased vascular density and abnormal
angio-architecture not only increase intrahepatic vascu-
lar resistance and decrease hepatocyte perfusion, but
also modulate the formation of portal-systemic collat-
erals, which are responsible for cirrhotic complications
such as portal hypertension [1]. Anti-angiogenesis has
been a therapeutic strategy for cirrhosis and cirrhotic
angiogenesis is regulated through two main pathways:
overexpression of grow factors and cytokines, especially
platelet derived growth factor (PDGF), transforming
growth factor (TGF)-β1, fibroblast growth factor (FGF)
and vascular endothelial growth factor (VEGF) in the
process of hepatic chronic wound healing. Hypoxia
contributes to up-regulation of the hepatic angiogenesis
signaling pathway [2]. Angiogenesis is characterized by
hypoxic stimulation and growth factor dependence.
VEGF is the only specific mitogen for endothelial cells
that undergoes mitosis and creates vascular tubes, stimu-
lating proliferation and migration of endothelial cells, and
thereby mediating physiological and pathological angio-
genesis [3]. VEGF is constitutively expressed in endothelial
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cells and hepatocytes at low levels under normal physio-
logical conditions. With hypoxia, hypoxia-inducible factor
(HIF)-1α induces expression of downstream target genes,
including VEGF and VEGF receptor (VEGFR) 2. Further-
more, hypoxia enhances VEGF mRNA stability to prevent
degradation and to increase transcription of VEGF [4].
Yiguanjian (YGJ) decoction was first described in ancient
traditional Chinese medicine and has been used to treat
hepatic diseases in China for centuries. YGJ decoction has
6 constituents: glehniae radix, ophiopogonis radix, angelicae
sinensis radix, dried rehmanniae radix, lycii fructus and
toosendan fructus. Research indicates that hepatoprotective
and anti-fibrogenic effects of YGJ against dimethylnitrosa-
mine (DMN)-induced hepatic injury. In DMN-induced
rats, oral administration of YGJ significantly reduced the
serum aspartate aminotransferase (AST) and alanine
transaminase (ALT), and inhibited accumulation of col-
lagen I, tissue inhibitor of metalloproteinase-1, and α-
smooth muscle actin (α-SMA) in hepatic tissues [5].
Recent research indicates that YGJ improved liver fi-
brosis by inhibiting the migration of bone marrow cells
into the liver, inhibiting their differentiation and sup-
pressing the proliferation of both progenitor cells and
hepatocytes in injured livers [6]. We previously re-
ported that YGJ exerts therapeutic effects on carbon
tetrachloride (CCl4)-induced cirrhosis in rats, by inhi-
biting hepatocyte apoptosis and hepatic stellate cell
(HSC) activation, as well as regulating the function of
Kupffer cells [7]. In addition, modified YGJ induced
HSC apoptosis via reactive oxygen species accumulation
and inducing the intrinsic apoptotic pathway in vitro [8].
Another modified YGJ induced hepatocarcinoma cell
anoikis in vitro, which may be associated with down-
regulation of p38 MAPK [9]. In our previous study, YGJ
was extracted using five different methods and we identi-
fied several active ingredients (iYGJ) that may suppress
liver fibrosis. iYGJ improved hepatic function and reduced
extracellular matrix (ECM) accumulation in CCl4-induced
cirrhosis in mice (data not published). However, how YGJ
and iYGJ prevents angiogenesis is uncertain. Thus, we in-
vestigated the effects of YGJ and iYGJ on angiogenesis
and studied the mechanisms underlying this process.
Methods
Materials
CCl4 was purchased from Guoyao Company (China).
Hydroxyproline (Hyp) standard was purchased from
Nakateitesuku Corporation (Japan). Biochemical parame-
ters kits were purchased from Nanjing Jiancheng Biotech
Company (China). Protein assay reagent was purchased
from Thermo Scientific (USA). Antibodies against α-SMA,
collagen I, CD31, VEGF and VEGFR2 were obtained from
Abcam (UK). Antibody against HIF-1α was obtained from
Biotechnology CO.,Ltd (China). Second antibodies were
obtained from LI-COR (USA). The RNA isolation kit,
reverse transcriptase kit and SYBR Green PCR Master Mix
were obtained from Takara (Japan). Sorafenib was used as
positive control in this experiment and was manufactured
by Bayer Pharmaceuticals (West Haven). Verbascoside and
ferulic acid were purchased from Chengdu Must Biological
Technology CO.,Ltd (China). Compound purities were
greater than 98.0 % as confirmed by high-performance li-
quid chromatography (HPLC).
Preparation of YGJ and iYGJ
Six herbs for the study were purchased from Shanghai
Huayu Chinese Herbs Co.,Ltd. (Shanghai, China), gleh-
niae radix (lot #2010092417); ophiopogonis radix (lot
#110307); angelicae sinensis radix (lot #2011020917);
dried rehmanniae radix (lot #2011010606); lycii fructus
(lot #2011032802); toosendan fructus (lot #2011020040).
All of them were identified by Dr. Wang of Shanghai
University of Traditional Chinese Medicine. A voucher
specimen of each species was deposited at the Herbarium
of the School of Pharmacy, Shanghai University of Trad-
itional Chinese Medicine. YGJ was prepared by the de-
partment of pharmaceutics, Shuguang hospital. Briefly,
YGJ herbs, including glehniae radix 10 g, ophiopogonis
radix 10 g, angelicae sinensis radix 10 g, dried rehmanniae
radix 18 g, lycii fructus 12 g and toosendan fructus 4.5 g,
were boiled under reflux three times. The filtrate was con-
centrated and dried to powder, and 1 g of the extract con-
tained 2.3 g herbs.
Extraction of iYGJ. The aqueous extract prepared as
above was mixed with three times volume of 95 % ethanol
and then kept overnight in a refrigerator. The supernatant
was evaporated in vacuo to remove, and then the aqueous
extract was chromatographed over a macroporous resin
D101 column and eluted with H2O, 30 %, 60 % and 95 %
EtOH. The 30 % EtOH elution was concentrated and
dried to powder and 1 g of the extract contained 47.1 g
herbs.
Analysis on the fingerprint of iYGJ by HPLC
The analysis of the iYGJ fingerprint was performed on a
Waters 2695 HPLC system equipped with a vacuum degas-
ser, a quaternary pump, an autosampler and a Waters 2487
UV detector system, connected to Waters Empower soft-
ware. A Diamonsil C18 column (250 mm× 4.6 mm, 5 μm)
was used for separation. Optimum separation was achieved
using gradient elution with 0.5 % formic acid in water (A)
and methanol (B): 0–10 min (5 %B–10 %B), 10–60 min
(10 %B–20 %B), 60–100 min (20 %B–40 %B), 100–
120 min (40–90 %B), 120–130 min (90 %B). The flow rate
was set at 1.0 ml/min and the injection volume was 20 μl.
Column temperature was maintained at 30 and UV detec-
tion was read at 330 nm. The HPLC fingerprint of iYGJ is
illustrated in Fig. 1.
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Animal model
C57BL/6 male mice, SPF, 20 ± 2 g, are supplied by the
Shanghai Experimental Animal Center, Chinese Academy
of Sciences. Animals were maintained on standard chow
in an air-conditioned room with a 12 h dark/light cycle.
All study protocols were approved by the Animal Ethics
Committee of Shanghai University of Traditional Chinese
Medicine.
Cirrhosis was induced by 10 % CCl4 (2 ml/kg, ip) di-
luted with olive oil, 3 times a week for 6 weeks. Con-
trols (n = 10) were given olive oil only. From week 4 to
week 6, CCl4-injected mice were divided into four
groups (n = 10 each group except for the placebo group
n = 15) and then subsequently treated with sorafenib
(4 mg/kg), YGJ (4 g/kg), iYGJ (0.2 g/kg) and placebo
(water) respectively by gavages, once a day. The con-
trols were given water. In the same time, CCl4 or olive
oil was injected respectively.
All mice were sacrificed after pentobarbital anesthesia.
Blood samples were obtained from interior vena cava, cen-
trifuged at 3,000 rpm for 15 min, and serum was kept for
serum biochemistry tests. Liver tissue specimens were
taken from the right hepatic lobe and fixed in 10 %
phosphate-buffered formaldehyde, routinely processed, and
then embedded in paraffin. Additional liver tissues were
snap-frozen in liquid nitrogen and stored at -70 °C for
later analysis.
Serum biochemistry and Hyp assay
Serum biochemistries—ALT, AST and albumin (ALB)—-
were measured as indicated by their assay standard kits.
Hyp assay of liver tissue was conducted on a modified ver-
sion of a method previously described [10]. Liver tissue
was homogenized and hydrolyzed in 6 N HCl at 110 °C
for 18 h. The hydrolysate was filtered and to this
chloramine-T was added (final concentration 2.5 mM).
The mixture was then treated with 410 mM paradigm
ethyl-amino-benzaldehyde and incubated for 30 min at
60 oC. Finally samples were read at λ560 nm.
Hepatic histopathology and immunohistochemistry
Hepatic histopathology and immunohistochemistry were
assessed by staining paraffinized liver sections (4 μm) with
hematoxylin and eosin (H&E), and Sirius red. For immu-
nohistochemistry, sections was incubated with primary
antibody (α-SMA 1:200, collagen I 1:250, CD31 1:200, and
VEGF 1:200) overnight, and then incubated with second-
ary labeled polymer HRP antibody for 1 h followed by
DAB staining. Collagen I was semi-quantified using image
analysis software. Five fields of each section were ran-
domly selected and values are expressed as means of five
animals per group.
Western blot
Liver samples were homogenized for 10 s at 10,000 rpm 3
times. Total protein was measured using a protein assay
reagent, and 50 μg protein was separated by SDS-PAGE
and then electrophoretically transferred to nitrocellulose
membranes. After incubation in blocking buffer, the mem-
brane was incubated with primary antibody (α-SMA
1:1,000, CD31 1:1,000, VEGF 1:1,000, VEGFR2 1:1,000,
and HIF-1α 1:1,000) at 4 °C overnight, followed by incuba-
tion with secondary antibody at room temperature for 1 h.
Immunoblots were visualized with an infrared imaging
system (Odyssey). Finally, the membrane subsequently
was treated with anti-GAPDH antibody.
Fig. 1 Main HPLC fingerprinting of iYGJ decoction. S1: verbascoside; S2: ferulic acid
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RNA isolation and RT-PCR
Total RNA was extracted from snap-frozen liver tissue
samples according to kit instruction. Total RNA was re-
verse transcribed using reverse transcriptase kit accord-
ing to the manufacturer’s guidelines. Primers for real time
reverse transcription PCR (RT-PCR) were designed and
synthesized by Takara (Japan). Primers used for RT-PCR
are as follows:
VEGF forward primer, 5′-GAAAGGGTCAAAAAACG
AAAGCG-3′,
VEGF reverse primer, 5′-TCTGCGGATCTTGGACA
AACAA-3′,
VEGFR2 forward primer, 5′-TGCCTACCTCACCTGT
TTCC-3′,
VEGFR2 reverse primer, 5′-CTCTTTCGCTTACTGT
TCTGGAG-3′,
HIF-1α forward primer, 5′-GGACGATGAACATCAA
GTCAGCA-3′
HIF-1α reverse primer, 5′-AGGAATGGGTTCACAA
ATCAGCA-3′
GAPDH forward primer, 5′-CTTTGGCATTGTGGA
AGGGCTC-3′,
GAPDH reverse primer, 5′-GCAGGGATGATGTTCT
GGGCAG-3′,
GAPDH expression was used as an internal control.
Initial denaturation was performed at 95 °C for 30 s,
followed by 40 cycles of 95 oC denaturing for 5 s, and
extension at 60 °C for 30 s. SYBR Green fluorescent in-
tensity of specific double-strand reflecting the amplicon
amount was read after each elongation step at an add-
itional acquisition temperature. To verify specificity of
the amplification reaction, melting curve analysis was
performed. Relative gene expression was presented using
the ΔΔCT method. RT-PCR was carried out using the
ABI ViiA7 sequence detector (Applied Biosystems).
Statistical analysis
All data were expressed as means ± SD. Statistical ana-
lysis was performed with SPSS software, version 17.0.
Data were analyzed using homogeneity of variances and
one-way analysis of variance (ANOVA). P-values less
than 0.05 were considered statistically significant.
The animal model was from another study from which
controls were shared. Data for ALT, AST, ALB, Hyp and
collagen I area were shared [11].
Results
YGJ and iYGJ against CCl4-induced cirrhosis
At the end of the 6th week, serum ALT and AST activ-
ity were significantly higher in the CCl4 model group
than in controls (P < 0.05). Sorafenib, YGJ and iYGJ re-
duced serum ALT and AST activity. Moreover, YGJ and
iYGJ reversed decreased ALB induced by CCl4 (P < 0.05)
(Table 1).
H&E staining revealed hepatocytes arranged in cords
from central veins to portal area, with intact hepatic
lobules in normal control mice. Damaged lobules and
extensive necroinflammatory lesions were visible in CCl4
group livers. Compared to the CCl4 group, necroinflam-
matory hepatic lesions were reduced in groups treated
with sorafenib, YGJ and iYGJ (Fig. 2a). Sirius red stain-
ing confirmed that modest collagen was present in the
area of the portal and central veins in normal control
mice, but in the CCl4 group, bridging collagen connect-
ing the central veins and neighboring portal areas in-
creased, and collagen fiber deposition was increased
and pseudonodules were present. In contrast, in the
Fig. 2 Effects of YGJ and iYGJ on CCl4-induced liver injury. Histopathology was assessed with H&E (a, 200×) and Sirius red (b, 100×)
Table 1 Serum ALT, AST and ALB in each group (means ± SD)
Group n ALT(IU/L) AST(IU/L) ALB(g/L)
Control 10 22.3 ± 2.9 31.4 ± 4.8 32.4 ± 2.2
CCl4 15 121.7 ± 30.0
# 67.6 ± 14.6 # 29.3 ± 1.8 #
CCl4 + Sorafenib 10 73.8 ± 16.7
#* 52.6 ± 8.7#* 31.6 ± 1.2
CCl4 + YGJ 10 77.9 ± 14.5
#* 52.8 ± 9.5#* 32.6 ± 3.2*
CCl4 + iYGJ 10 72.6 ± 12.8
#* 44.5 ± 8.8#* 32.7 ± 1.3*
Note: #, compared to control group P < 0.05; *, compared to CCl4
group, P < 0.05
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sorafenib, YGJ and iYGJ groups, hepatic collagen de-
position were significantly attenuated (Fig. 2b).
Consistently, hepatic Hyp content was significantly in-
creased after CCl4 treatment compared with controls.
However, sorafenib, YGJ or iYGJ treatment decreased Hyp
content compared with CCl4 treated animals (P < 0.05;
Table 2).
Immunohistochemistry indicated that accumulation of
the active HSC marker α-SMA in livers increased in the
CCl4 group. This change was consistent with protein ex-
pression of α-SMA analyzed by Western blot, which also
increased after CCl4 injection. Increased expression of
α-SMA was followed by enhanced collagen I synthesis.
Semi-quantification of immunohistochemical staining
revealed that collagen I increased sharply after CCl4 in-
jection, 6.5-fold above control values. After treatment
with sorafenib, YGJ or iYGJ, expression of α-SMA de-
creased according to immunohistochemistry data, and
this agreed with data confirmed by Western blot. Thus,
collagen I expression was significantly suppressed by so-
rafenib, YGJ or iYGJ treatment (P < 0.05; Fig. 3).
Effects of YGJ and iYGJ on angiogenesis
Immunohistochemistry revealed that CD31 and VEGF ex-
pression in the liver was up regulated after CCl4 treatment
compared to controls. Notably, VEGF was observed not
only in the hepatic sinusoid, but also in injured hepato-
cytes adjacent to the fibrotic septa around the portal area.
In contrast, positive staining for CD31 and VEGF were
decreased in the YGJ, iYGJ and sorafenib groups (Fig. 4a).
Data from Western blot indicate that sorafenib, YGJ or
iYGJ treatment reduced over-expression of CD31 and
VEGF induced by CCl4, which is consistent with results of
immunohistochemistry (P < 0.05; Fig. 4b, c, d). Moreover,
VEGF mRNA was significantly increased in the CCl4
group compared to controls, but after sorafenib, YGJ or
iYGJ treatment expression significantly decreased com-
pared CCl4 treatment (P < 0.05; Fig. 4e). We next mea-
sured the effect of iYGJ on VEGFR2 with Western blot
and PCR and noted that after CCl4 treatment, VEGFR2
expression was up regulated, but in the iYGJ treated
group, VEGFR2 decreased markedly compared to the
CCl4 group (P < 0.05; Fig. 4f, g, h).
Western blot and RT-PCR combined to indicate that
expression of HIF-1α was significantly increased in the
CCl4 group compared controls. As expected, protein and
gene expressions of HIF-1α were all down regulated
Fig. 3 Effects of YGJ and iYGJ on CCl4-induced activation of HSC. a Immunohistochemistry of liver sections for α-SMA and collagen I (200×). b Intensity
of collagen I (A, below) was assessed by image analysis. n = 5. c Western blot quantified protein expression of α-SMA. GAPDH expression was a control
for equal protein loading. d Quantification of band intensities of expressed proteins. n = 3. Quantitative data were reported as means ± SD. #, compared
to control group P < 0.05; *, compared to CCl4 model group P < 0.05
Table 2 Hyp content in each group (means ± SD)
Group n Hyp (μg/g)
Control 10 133.0 ± 31.3
CCl4 15 411.2 ± 67.6
#
CCl4 + Sorafenib 10 276.7 ± 30.8
#*
CCl4 + YGJ 10 240.5 ± 45.4
#*
CCl4 + iYGJ 10 254.5 ± 29.9
#*
Note: #, compared to control group P < 0.05; *, compared to CCl4
group, P < 0.05
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Fig. 4 Effects of YGJ and iYGJ on CCl4-induced liver angiogenesis. a Immunohistochemistry of liver sections for CD31 and VEGF (400×). b, f Western
blot quantified protein expression of CD31, VEGF and VEGFR2. GAPDH expression was a control for equal protein loading. c, d, g Quantification of
band intensities of expressed proteins. n = 3. e, h VEGF and VEGFR2 mRNA expression was measured by RT-PCR. n = 3. Quantitative data were reported
as means ± SD. #, compared to control group P < 0.05; *, compared to CCl4 model group P < 0.05
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significantly by YGJ and iYGJ (P < 0.05). Also, the extent
of YGJ and iYGJ in HIF-1α protein down-regulation was
greater than after sorafenib treatment (Fig. 5).
Discussion
Angiogenesis is a complex biological process in which
new capillaries form, initiated from vascular sprouts based
on pre-existing vascular construction. Neo-angiogenesis is
an important pathophysiological feature of liver scarring,
as evidenced by the presence of newly created blood
vessels in fibrous septa around the portal area [1]. Many
studies suggest that the multiple tyrosine kinase inhibitor
(e.g. sorafenib and sunitinib) may have antifibrotic effects
[12], but it cannot easily be applied for human liver dis-
eases due to serious side-effects. Angiogenesis signaling is
involved in the wound healing response in hepatic fibrosis,
contributing not only to ECM deposition, but also to
portal hypertension [2]. Classic angiogenenic mediators,
notably VEGF and PDGF, drive both angiogenic and fibro-
genic responses, and may also foster a milieu permissive
for the development of hepatocellular carcinoma [13].
Therefore, safe and effective therapies targeting key mole-
cules involved in anti-angiogenenic progression are ur-
gently needed to prevent hepatic fibrosis.
Here, we show that YGJ and iYGJ effectively ameliorated
liver injury stimulated by CCl4 in mice, improved liver
function, decreased inflammatory infiltration and liver ne-
crosis, decreased ECM deposition and decreased Hyp.
Moreover, α-SMA and collagen I expression (secreted
mainly by HSC) were inhibited by YGJ and iYGJ. Thus,
antifibrotic effects of YGJ and iYGJ are partially mediated
by inhibiting activation of HSC in CCl4-induced cirrhotic
mice.
Hepatic sinusoids are lined by fenestrated endothelial
cells which lack a basement membrane, and intercellular
junctions are absent. This anatomy facilitates rapid ex-
change between plasma and hepatocytes. Morphologically,
cirrhosis may be accompanied by widening of the space of
Disse, subendothelial deposition of collagen and basement
membrane material. These changes are often referred to
as “capillarization of sinusoids”. Structural change reduces
transport across the sinusoidal walls, leading to functional
impairment. CD31 is identified as a marker generally used
for labeling continuous endothelial cells, which can be
expressed by the newly formed hepatic vasculature. Ac-
cordingly, the content and distribution of CD31 could
reflect the condition of angiogenesis. In our study, immu-
nohistochemistry and Western blot confirmed CD31
expression was increased in the liver of cirrhotic mice
induced by CCl4, indicating that angiogenesis is a process
of cirrhosis. After administration of YGJ or iYGJ, CD31
expression was decreased significantly, and these effects
were similar to those conveyed by sorafenib (positive con-
trol). Sorafenib, a kinase inhibitor that targets multiple
tyrosine kinases, is confirmed modulate angiogenesis and
fibrosis. Thus, YGJ and iYGJ have the potential to inhibit
angiogenesis of cirrhosis.
Hepatic angiogenesis is strongly linked to progressive
fibrogenesis, although mechanisms of direct interac-
tions between both processes are not yet entirely clear.
Scar development and disorganization of the vascula-
ture in cirrhosis may aggravate local hypoxia. Recently,
hepatic disturbances in microcirculation, hypoxia, and
Fig. 5 Effects of YGJ and iYGJ on HIF-1α. a Western blot quantified protein expression of HIF-1α. GAPDH expression was a control for equal protein
loading. b Quantification of band intensities of expressed proteins. n = 3. c HIF-1α mRNA expression was measured by RT-PCR. n = 3. Quantitative data
were reported as means ± SD, #, compared to control group P < 0.05; *, compared to CCl4 model group P < 0.05
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angiogenesis have been documented to occur well before
the onset of cirrhotic lesions in injured livers [14]. HIF-1,
a heterodimeric comprised of a labile alpha subunit (HIF-
1α) and a stable beta subunit (HIF-1β), is a major tran-
scription factor for regulating oxygen homeostasis. The
alpha subunit is regulated strictly by the concentration of
oxygen, whereas the beta subunit is expressed in numer-
ous cell types, and is not influenced by oxygen tension.
Normally, the half-life of HIF-1α is very short. It is synthe-
sized and degraded dynamically. When the concentration
of oxygen is lowered (≤2 %), oxygen-dependent degrad-
ation of HIF-1α is inhibited [15]. The excessive accumula-
tion of HIF-1α would induce transcription of downstream
genes, including VEGF, PDGF and FGF [4, 14]. In particu-
lar, 70–80 % expression of VEGF mRNA depends on HIF-
1α [16]. Our data indicate that YGJ and iYGJ significantly
reduced HIF-1α and its downstream target gene, VEGF,
at the protein and mRNA levels. Biological activity of
VEGF is mediated mainly via VEGFR1 and VEGFR2. In
the CCl4 model, vessel formation was associated with
strong expression of VEGF and its receptor, VEGFR2
[17]. We report that iYGJ significantly inhibited expres-
sion of VEGFR2 in a CCl4 model. This indicates that
the anti-angiogenic effect of YGJ and iYGJ was like
caused by inhibiting the HIF-1α/VEGF signaling path-
way. In addition, cirrhosis experimental model studies
and analysis of patients with cirrhosis induced by hepatitis
B virus infection indicate that hepatic VEGF expression
mainly focuses on expansive sinusoid endothelial cells and
severely injured hepatocytes [18–20]. In this current study,
VEGF was observed in the cytoplasm of injured hepato-
cytes adjacent to fibrotic septa around the portal area,
which may be explained by regional hypoxia. It is sug-
gested that injured hepatocytes may be one of the
sources of VEGF under hypoxic condition in CCl4-
induced cirrhosis.
Conclusions
In conclusion, YGJ and iYGJ had anti-angiogenic effects in
a CCl4-induced cirrhosis mouse model and how this oc-
curred is likely through improvement of hepatic hypoxia
and inhibition of the HIF-1α/VEGF signaling pathway.
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